Unknown

Dataset Information

Efficient correction of Duchenne muscular dystrophy mutations by SpCas9 and dual gRNAs.


ABSTRACT: CRISPR gene therapy is one promising approach for treatment of Duchenne muscular dystrophy (DMD), which is caused by a large spectrum of mutations in the dystrophin gene. To broaden CRISPR gene editing strategies for DMD treatment, we report the efficient restoration of dystrophin expression in induced myotubes by SpCas9 and dual guide RNAs (gRNAs). We first sequenced 32 deletion junctions generated by this editing method and revealed that non-homologous blunt-end joining represents the major indel type. Based on this predictive repair outcome, efficient in-frame deletion of a part of DMD exon 51 was achieved in HEK293T cells with plasmids expressing SpCas9 and dual gRNAs. More importantly, we further corrected a frameshift mutation in human DMD (exon45del) fibroblasts with S

SUBMITTER: Xiang X 

PROVIDER: S-EPMC8039775 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature